BioLineRx (NASDAQ:BLRX) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of BioLineRx in a research report on Wednesday.

BioLineRx Price Performance

BLRX stock opened at $0.45 on Friday. The firm has a market cap of $36.08 million, a PE ratio of -1.00 and a beta of 1.48. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The firm’s 50 day moving average price is $0.53 and its 200-day moving average price is $0.63. BioLineRx has a one year low of $0.39 and a one year high of $1.93.

BioLineRx (NASDAQ:BLRX) last released its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $5.39 million for the quarter, compared to analysts’ expectations of $3.93 million. On average, equities research analysts anticipate that BioLineRx will post -0.25 EPS for the current year.

Institutional Trading of BioLineRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PVG Asset Management Corp purchased a new stake in BioLineRx in the second quarter valued at approximately $70,000. CVI Holdings LLC purchased a new stake in BioLineRx in the second quarter valued at approximately $462,000. Finally, Atria Investments Inc raised its position in BioLineRx by 27.9% in the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the period. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.